Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL.
Diepstraten ST, et al. Among authors: fischer kc.
Cancer Cell. 2024 Apr 23:S1535-6108(24)00128-4. doi: 10.1016/j.ccell.2024.04.004. Online ahead of print.
Cancer Cell. 2024.
PMID: 38670091